Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

Scott B. Sellinger, MD, FACS, discusses the challenges facing urologists, the loss of telehealth flexibility, and why bipartisan action remains urgent.

A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.